Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs
Osteoarthritis (OA) is a highly prevalent degenerative joint disease involving joint cartilage and its surrounding tissues. OA is the leading cause of pain and disability worldwide. At present, there are no disease-modifying OA drugs, and the primary therapies include exercise and nonsteroidal anti-inflammatory drugs until total joint replacement at the end-stage of the disease.
In this review, we summarized the current state of knowledge in genetic and epigenetic associations and risk factors for OA and their potential diagnostic and therapeutic applications.
Genome-wide association studies and analysis of epigenetic modifications (such as miRNA expression, DNA methylation and histone modifications) conducted across various populations support the notion that there is a genetic basis for certain subsets of OA pathogenesis.
With recent advances in the development of genome editing technologies such as the CRISPR-Cas9 system, these genetic and epigenetic alternations in OA can be used as platforms from which potential biomarkers for the diagnosis, prognosis, drug response, and development of potential personalized therapeutic targets for OA can be approached. Furthermore, genome editing has allowed the development of “designer” cells, whereby the receptors, gene regulatory networks, or transgenes can be modified as a basis for new cell-based therapies.
KeywordsGenetics Gene editing Personalized medicine Osteoarthritis
We acknowledge that this review is not exhaustive and the authors apologize to those whose work was not included due to space limitations. This study was supported in part by NIH Grants AR50245, AR48852, AG15768, AR48182, AG46927, OD10707, DK108742, EB018266, AR057235, AR073752, the Arthritis Foundation, and the Nancy Taylor Foundation for Chronic Diseases.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
There are no animal experiments carried out for this article.
- 25.Southam L, Rodriguez-Lopez J, Wilkins JM, Pombo-Suarez M, Snelling S, Gomez-Reino JJ, et al. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet. 2007;16:2226–32.PubMedCrossRefGoogle Scholar
- 28.Parrish WR, Byers BA, Su D, Geesin J, Herzberg U, Wadsworth S, et al. Intra-articular therapy with recombinant human GDF5 arrests disease progression and stimulates cartilage repair in the rat medial meniscus transection (MMT) model of osteoarthritis. Osteoarthritis Cartilage. 2017;25:554–60.PubMedCrossRefGoogle Scholar
- 31.Castaño Betancourt MC, Cailotto F, Kerkhof HJ, Cornelis FM, Doherty SA, Hart DJ, et al. Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci U S A. 2012;109:8218–23.PubMedPubMedCentralCrossRefGoogle Scholar
- 42.Roach HI, Yamada N, Cheung KS, Tilley S, Clarke NM, Oreffo RO, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum. 2005;52:3110–24.PubMedCrossRefGoogle Scholar
- 43.de Andrés MC, Imagawa K, Hashimoto K, Gonzalez A, Roach HI, Goldring MB, et al. Loss of methylation in CpG sites in the NF-kappaB enhancer elements of inducible nitric oxide synthase is responsible for gene induction in human articular chondrocytes. Arthritis Rheum. 2013;65:732–42.PubMedPubMedCentralCrossRefGoogle Scholar
- 61.Kim SJ, Kim CH, An B, Ha KS, Hong SH, Kim KS. Effects of clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) protein 9 system-based deletion of miR-451 in mouse mmbryonic stem cells on their self-renewal and hematopoietic differentiation. Tissue Eng Regen Med. 2017;14:179–85.PubMedPubMedCentralCrossRefGoogle Scholar
- 78.Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417–25.Google Scholar
- 81.Im HJ, Liu Z, Li X, Bethea J. Inhibition of glial NF-KB abolishes pain in knee osteoarthritis model. Osteoarthritis Cartilage. 2016;24:S35.Google Scholar